OBJECTIVE ASSESSMENT - EXAM
Pharmacology
V3 Exam
RN HESI | Actual Q&As + Rationales
100 100% 2026/2027
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
Pharmacokinetics & Pharmacodynamics CNS & Psychiatric Medications
Cardiovascular & Antihypertensive Drugs Endocrine & Respiratory Pharmacology
Antibiotics & Antimicrobial Agents
COVER PAGE - 1
, SECTION 1 | Pharmacokinetics & Pharmacodynamics | Q1-Q20 | RN HESI Pharmacology V3 2026/2027
Q1 Question 1 of 100
A 67-year-old patient receives an oral dose of levothyroxine 100 mcg daily. The nurse understands that the drug's
bioavailability is significantly affected by first-pass metabolism in the liver. Which statement best describes the
first-pass effect?
A. Drug is partially metabolized in the gut before reaching systemic circulation, reducing the amount of
active drug available
B. Drug is completely inactivated by the kidneys before reaching target tissues
C. Drug bypasses the liver entirely and goes straight to systemic circulation
D. Drug accumulates in adipose tissue and is slowly released over time
Correct Answer: A
Rationale:
The first-pass effect occurs when an orally administered drug is absorbed through the GI tract and enters the portal
circulation, where it passes through the liver before reaching systemic circulation. The liver metabolizes a portion of the
drug, reducing the active amount available. This is why oral doses are often higher than equivalent IV doses. The
kidneys do not perform first-pass metabolism, and the drug does not bypass the liver.
Q2 Question 2 of 100
A 54-year-old patient with cirrhosis is prescribed a medication normally metabolized by hepatic enzymes. The
nurse anticipates that hepatic impairment will most directly affect which pharmacokinetic phase?
A. Distribution, by preventing drug from binding to plasma proteins
B. Metabolism, by reducing the liver's ability to biotransform the medication
C. Excretion, by preventing drug elimination through the bile ducts
D. Absorption, by slowing drug movement across the intestinal wall
Correct Answer: B
Rationale:
The liver is the primary site of drug biotransformation (metabolism) through phase I (cytochrome P450) and phase II
(conjugation) reactions. Cirrhosis impairs these enzymes, prolonging drug half-life and increasing the risk of toxicity.
Absorption occurs in the GI tract, distribution depends on blood flow and protein binding, and excretion is primarily
renal. While severe liver disease can affect protein binding and biliary excretion, the most direct impact is on
metabolism.
Q3 Question 3 of 100
A 45-year-old patient with chronic kidney disease has a creatinine clearance of 25 mL/min. The nurse understands
that this will primarily affect which pharmacokinetic parameter of renally excreted medications?
A. Renal excretion rate leading to drug accumulation
B. Hepatic first-pass metabolism
C. Absorption rate from the gastrointestinal tract
RN HESI Pharmacology V3 - 2026/2027 | Passing Score: 75% | Page 1 of 42
, D. Volume of distribution in adipose tissue
Correct Answer: A
Rationale:
Renal excretion is the primary route of elimination for many drugs and their active metabolites. A reduced creatinine
clearance (normal is 90-120 mL/min) means the kidneys cannot effectively filter and excrete the drug, leading to
accumulation and potential toxicity. Absorption, distribution, and hepatic metabolism are not directly affected by renal
function. Drug doses must be adjusted based on creatinine clearance to avoid toxicity.
Q4 Question 4 of 100
A 38-year-old patient receiving IV morphine experiences pain relief within minutes. The nurse explains that the
rapid onset is due to which pharmacokinetic property of intravenous administration?
A. Bypassing first-pass metabolism and achieving 100% bioavailability with immediate systemic
distribution
B. Slow absorption from muscle tissue into the bloodstream
C. Complete degradation in the gastrointestinal tract
D. Prolonged binding to plasma proteins
Correct Answer: A
Rationale:
Intravenous administration delivers the drug directly into systemic circulation, bypassing first-pass hepatic metabolism
and achieving 100% bioavailability. This produces immediate therapeutic effects because the drug reaches target
receptors without delay. Oral and intramuscular routes require absorption time. IV drugs do not undergo GI degradation
or prolonged protein binding as the primary reason for rapid onset.
Q5 Question 5 of 100
A 60-year-old patient is taking warfarin, which is highly protein-bound. The provider adds
sulfamethoxazole-trimethoprim, also highly protein-bound. The nurse anticipates that this interaction will produce
which effect on warfarin levels?
A. No change because protein binding is not affected by concurrent medications
B. Decreased warfarin effect because of enhanced hepatic metabolism
C. Decreased free warfarin levels because more binds to plasma proteins
D. Increased free warfarin levels because sulfamethoxazole displaces warfarin from protein binding sites
Correct Answer: D
Rationale:
When two highly protein-bound drugs are administered together, they compete for binding sites on plasma proteins
(mainly albumin). Sulfamethoxazole displaces warfarin from albumin, increasing the free (active) warfarin concentration
and raising the INR, which increases bleeding risk. The total warfarin level may not change, but the pharmacologically
active free fraction does. This is a classic displacement interaction.
RN HESI Pharmacology V3 - 2026/2027 | Passing Score: 75% | Page 2 of 42
, Q6 Question 6 of 100
A 72-year-old patient receives digoxin for heart failure. Aging produces several physiologic changes that affect
drug pharmacokinetics. Which age-related change most directly increases the risk of digoxin toxicity in older
adults?
A. Decline in renal function that reduces digoxin elimination and prolongs half-life
B. Enhanced hepatic enzyme activity that accelerates drug metabolism
C. Increased gastric acid production that accelerates drug absorption
D. Increased lean body mass that enhances drug distribution
Correct Answer: A
Rationale:
Digoxin is primarily eliminated by the kidneys, and renal function naturally declines with age (creatinine clearance
decreases approximately 1 mL/min per year after age 40). Reduced renal excretion prolongs digoxin half-life and
increases serum levels, raising toxicity risk. Older adults also have reduced lean body mass and total body water, but
the most clinically significant change for digoxin is the decline in renal function. Hepatic metabolism is less relevant for
digoxin.
Q7 Question 7 of 100
A 50-year-old patient is prescribed a medication with a narrow therapeutic index. The nurse understands that
drugs with a narrow therapeutic index require careful monitoring because:
A. The drug is metabolized so rapidly that doses must be given hourly
B. The therapeutic dose is much lower than the toxic dose, leaving little margin of safety
C. The toxic dose is significantly higher than the therapeutic dose, allowing wide dosing flexibility
D. The medication has no side effects at any dose
Correct Answer: B
Rationale:
A narrow therapeutic index means the difference between the minimum effective concentration and the minimum toxic
concentration is small. Drugs like warfarin, digoxin, lithium, and phenytoin require serum level monitoring to ensure
therapeutic efficacy without toxicity. Wide dosing flexibility is dangerous with such drugs, and they typically have
well-documented side effects. Metabolism rate is not the defining characteristic.
Q8 Question 8 of 100
A 48-year-old patient with epilepsy is taking phenytoin, which follows zero-order (Michaelis-Menten) kinetics at
therapeutic doses. The nurse understands that this pharmacokinetic property has which important clinical
implication?
A. Small dose increases can cause disproportionate increases in serum drug levels
B. Doubling the dose will double the serum drug concentration
C. The drug is eliminated at a constant rate regardless of dose
D. Therapeutic drug monitoring is unnecessary
Correct Answer: A
RN HESI Pharmacology V3 - 2026/2027 | Passing Score: 75% | Page 3 of 42
Pharmacology
V3 Exam
RN HESI | Actual Q&As + Rationales
100 100% 2026/2027
QUESTIONS VERIFIED ANSWERS EDITION
TOPICS COVERED
Pharmacokinetics & Pharmacodynamics CNS & Psychiatric Medications
Cardiovascular & Antihypertensive Drugs Endocrine & Respiratory Pharmacology
Antibiotics & Antimicrobial Agents
COVER PAGE - 1
, SECTION 1 | Pharmacokinetics & Pharmacodynamics | Q1-Q20 | RN HESI Pharmacology V3 2026/2027
Q1 Question 1 of 100
A 67-year-old patient receives an oral dose of levothyroxine 100 mcg daily. The nurse understands that the drug's
bioavailability is significantly affected by first-pass metabolism in the liver. Which statement best describes the
first-pass effect?
A. Drug is partially metabolized in the gut before reaching systemic circulation, reducing the amount of
active drug available
B. Drug is completely inactivated by the kidneys before reaching target tissues
C. Drug bypasses the liver entirely and goes straight to systemic circulation
D. Drug accumulates in adipose tissue and is slowly released over time
Correct Answer: A
Rationale:
The first-pass effect occurs when an orally administered drug is absorbed through the GI tract and enters the portal
circulation, where it passes through the liver before reaching systemic circulation. The liver metabolizes a portion of the
drug, reducing the active amount available. This is why oral doses are often higher than equivalent IV doses. The
kidneys do not perform first-pass metabolism, and the drug does not bypass the liver.
Q2 Question 2 of 100
A 54-year-old patient with cirrhosis is prescribed a medication normally metabolized by hepatic enzymes. The
nurse anticipates that hepatic impairment will most directly affect which pharmacokinetic phase?
A. Distribution, by preventing drug from binding to plasma proteins
B. Metabolism, by reducing the liver's ability to biotransform the medication
C. Excretion, by preventing drug elimination through the bile ducts
D. Absorption, by slowing drug movement across the intestinal wall
Correct Answer: B
Rationale:
The liver is the primary site of drug biotransformation (metabolism) through phase I (cytochrome P450) and phase II
(conjugation) reactions. Cirrhosis impairs these enzymes, prolonging drug half-life and increasing the risk of toxicity.
Absorption occurs in the GI tract, distribution depends on blood flow and protein binding, and excretion is primarily
renal. While severe liver disease can affect protein binding and biliary excretion, the most direct impact is on
metabolism.
Q3 Question 3 of 100
A 45-year-old patient with chronic kidney disease has a creatinine clearance of 25 mL/min. The nurse understands
that this will primarily affect which pharmacokinetic parameter of renally excreted medications?
A. Renal excretion rate leading to drug accumulation
B. Hepatic first-pass metabolism
C. Absorption rate from the gastrointestinal tract
RN HESI Pharmacology V3 - 2026/2027 | Passing Score: 75% | Page 1 of 42
, D. Volume of distribution in adipose tissue
Correct Answer: A
Rationale:
Renal excretion is the primary route of elimination for many drugs and their active metabolites. A reduced creatinine
clearance (normal is 90-120 mL/min) means the kidneys cannot effectively filter and excrete the drug, leading to
accumulation and potential toxicity. Absorption, distribution, and hepatic metabolism are not directly affected by renal
function. Drug doses must be adjusted based on creatinine clearance to avoid toxicity.
Q4 Question 4 of 100
A 38-year-old patient receiving IV morphine experiences pain relief within minutes. The nurse explains that the
rapid onset is due to which pharmacokinetic property of intravenous administration?
A. Bypassing first-pass metabolism and achieving 100% bioavailability with immediate systemic
distribution
B. Slow absorption from muscle tissue into the bloodstream
C. Complete degradation in the gastrointestinal tract
D. Prolonged binding to plasma proteins
Correct Answer: A
Rationale:
Intravenous administration delivers the drug directly into systemic circulation, bypassing first-pass hepatic metabolism
and achieving 100% bioavailability. This produces immediate therapeutic effects because the drug reaches target
receptors without delay. Oral and intramuscular routes require absorption time. IV drugs do not undergo GI degradation
or prolonged protein binding as the primary reason for rapid onset.
Q5 Question 5 of 100
A 60-year-old patient is taking warfarin, which is highly protein-bound. The provider adds
sulfamethoxazole-trimethoprim, also highly protein-bound. The nurse anticipates that this interaction will produce
which effect on warfarin levels?
A. No change because protein binding is not affected by concurrent medications
B. Decreased warfarin effect because of enhanced hepatic metabolism
C. Decreased free warfarin levels because more binds to plasma proteins
D. Increased free warfarin levels because sulfamethoxazole displaces warfarin from protein binding sites
Correct Answer: D
Rationale:
When two highly protein-bound drugs are administered together, they compete for binding sites on plasma proteins
(mainly albumin). Sulfamethoxazole displaces warfarin from albumin, increasing the free (active) warfarin concentration
and raising the INR, which increases bleeding risk. The total warfarin level may not change, but the pharmacologically
active free fraction does. This is a classic displacement interaction.
RN HESI Pharmacology V3 - 2026/2027 | Passing Score: 75% | Page 2 of 42
, Q6 Question 6 of 100
A 72-year-old patient receives digoxin for heart failure. Aging produces several physiologic changes that affect
drug pharmacokinetics. Which age-related change most directly increases the risk of digoxin toxicity in older
adults?
A. Decline in renal function that reduces digoxin elimination and prolongs half-life
B. Enhanced hepatic enzyme activity that accelerates drug metabolism
C. Increased gastric acid production that accelerates drug absorption
D. Increased lean body mass that enhances drug distribution
Correct Answer: A
Rationale:
Digoxin is primarily eliminated by the kidneys, and renal function naturally declines with age (creatinine clearance
decreases approximately 1 mL/min per year after age 40). Reduced renal excretion prolongs digoxin half-life and
increases serum levels, raising toxicity risk. Older adults also have reduced lean body mass and total body water, but
the most clinically significant change for digoxin is the decline in renal function. Hepatic metabolism is less relevant for
digoxin.
Q7 Question 7 of 100
A 50-year-old patient is prescribed a medication with a narrow therapeutic index. The nurse understands that
drugs with a narrow therapeutic index require careful monitoring because:
A. The drug is metabolized so rapidly that doses must be given hourly
B. The therapeutic dose is much lower than the toxic dose, leaving little margin of safety
C. The toxic dose is significantly higher than the therapeutic dose, allowing wide dosing flexibility
D. The medication has no side effects at any dose
Correct Answer: B
Rationale:
A narrow therapeutic index means the difference between the minimum effective concentration and the minimum toxic
concentration is small. Drugs like warfarin, digoxin, lithium, and phenytoin require serum level monitoring to ensure
therapeutic efficacy without toxicity. Wide dosing flexibility is dangerous with such drugs, and they typically have
well-documented side effects. Metabolism rate is not the defining characteristic.
Q8 Question 8 of 100
A 48-year-old patient with epilepsy is taking phenytoin, which follows zero-order (Michaelis-Menten) kinetics at
therapeutic doses. The nurse understands that this pharmacokinetic property has which important clinical
implication?
A. Small dose increases can cause disproportionate increases in serum drug levels
B. Doubling the dose will double the serum drug concentration
C. The drug is eliminated at a constant rate regardless of dose
D. Therapeutic drug monitoring is unnecessary
Correct Answer: A
RN HESI Pharmacology V3 - 2026/2027 | Passing Score: 75% | Page 3 of 42
